196 related articles for article (PubMed ID: 37686291)
1. A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma.
Huang J; Liang R; Lu C; Lu L; Li S; Tang M; Huang X; Huang S; Mai R; Gao X; Li S; Zeng C; Lin Y; Ye J
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686291
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
Xia Y; Tang W; Qian X; Li X; Cheng F; Wang K; Zhang F; Zhang C; Li D; Song J; Zhang H; Zhao J; Yao A; Wu X; Wu C; Ji G; Liu X; Zhu F; Qin L; Xiao X; Deng Z; Kong X; Li S; Yu Y; Xi W; Deng W; Qi C; Liu H; Pu L; Wang P; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379737
[TBL] [Abstract][Full Text] [Related]
4. Camrelizumab: an investigational agent for hepatocellular carcinoma.
Xu B; Sun HC
Expert Opin Investig Drugs; 2022 Apr; 31(4):337-346. PubMed ID: 34937475
[TBL] [Abstract][Full Text] [Related]
5. Hepatectomy combined with apatinib and camrelizumab for CNLC stage IIIb hepatocellular carcinoma: a phase II trial protocol.
Huang JT; Zhong JH; Zhang J; Gong WF; Ma L; Li LQ; Xiang BD
BMJ Open; 2023 Sep; 13(9):e067730. PubMed ID: 37770273
[TBL] [Abstract][Full Text] [Related]
6. Preventing Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy With Active Hexose-correlated Compound Derived From Lentinula edodes Mycelia.
Kamiyama T; Orimo T; Wakayama K; Kakisaka T; Shimada S; Nagatsu A; Asahi Y; Aiyama T; Kamachi H; Taketomi A
Integr Cancer Ther; 2022; 21():15347354211073066. PubMed ID: 35075934
[TBL] [Abstract][Full Text] [Related]
7. Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study.
Li X; Zhang Q; Lu Q; Cheng Z; Liu F; Han Z; Yu X; Yu J; Liang P
Front Immunol; 2022; 13():1023983. PubMed ID: 36389778
[TBL] [Abstract][Full Text] [Related]
8. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.
Kamiyama T; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamachi H; Yamashita K; Shimamura T; Taketomi A
World J Surg Oncol; 2017 Aug; 15(1):156. PubMed ID: 28830473
[TBL] [Abstract][Full Text] [Related]
9. Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma.
Zhu XD; Huang C; Shen YH; Xu B; Ge NL; Ji Y; Qu XD; Chen L; Chen Y; Li ML; Zhu JJ; Tang ZY; Zhou J; Fan J; Sun HC
Ann Surg Oncol; 2023 May; 30(5):2782-2790. PubMed ID: 36178565
[TBL] [Abstract][Full Text] [Related]
10. Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report.
Chen Z; Chen Z; Fan W; Zou Y; Zhang Y; Shi N; Jin H
World J Surg Oncol; 2023 Jan; 21(1):29. PubMed ID: 36721173
[TBL] [Abstract][Full Text] [Related]
11. Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma.
Yang SY; Wang CC; Chen KD; Liu YW; Lin CC; Chuang CH; Tsai YC; Yao CC; Yen YH; Hsiao CC; Hu TH; Tsai MC
BMC Cancer; 2021 Jan; 21(1):70. PubMed ID: 33446127
[TBL] [Abstract][Full Text] [Related]
12. [Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study].
Yuan GS; He WM; Hu XY; Li Q; Zang MY; Cheng X; Huang W; Ruan J; Wang JJ; Hou JL; Chen JZ
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):326-331. PubMed ID: 33979958
[No Abstract] [Full Text] [Related]
13. Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review.
Liu XL; Li XZ; Chu YF; Liu F; Tian H
Front Oncol; 2024; 14():1280805. PubMed ID: 38601767
[TBL] [Abstract][Full Text] [Related]
14. Hepatectomy combined with sorafenib in patients with intermediate-advanced hepatocellullar carcinoma.
Zhu H; Ye B; Qiao Z; Zeng L; Li Q
J BUON; 2019; 24(4):1382-1389. PubMed ID: 31646781
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.
Yang Z; Chen G; Cui Y; Xiao G; Su T; Yu J; Zhang Z; Han Y; Yang K; Jin L
Cancer Biol Ther; 2019; 20(3):321-327. PubMed ID: 30332553
[TBL] [Abstract][Full Text] [Related]
16. The effect of apatinib in the treatment of sorafenib resistant metastatic hepatocellular carcinoma: A case report.
Han Z; He Z; Wang C; Wang Q
Medicine (Baltimore); 2018 Dec; 97(49):e13388. PubMed ID: 30544412
[TBL] [Abstract][Full Text] [Related]
17. Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study.
Chong CC; Wong GL; Wong VW; Ip PC; Cheung YS; Wong J; Lee KF; Lai PB; Chan HL
Aliment Pharmacol Ther; 2015 Jan; 41(2):199-208. PubMed ID: 25413146
[TBL] [Abstract][Full Text] [Related]
18. [Application and prospect of PD-1 or PD-L1 inhibitor in advanced hepatocellular carcinoma].
Mao J; Yan Q; Shen ZH; Sun X; Zheng SS
Zhonghua Wai Ke Za Zhi; 2021 Oct; 59(10):875-880. PubMed ID: 34619915
[TBL] [Abstract][Full Text] [Related]
19. [A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration].
Kim Y; Hosoda Y; Kakita N; Yamada Y; Yamasaki M; Nishino M; Okano M; Nagai K; Yasui M; Tsujinaka T
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2124-6. PubMed ID: 25731444
[TBL] [Abstract][Full Text] [Related]
20. [A Case of Advanced Hepatocellular Carcinoma Successfully Treated with Liver Resection after Administration of Sorafenib].
Kodai S; Kanazawa A; Kinoshita M; Hamano G; Nishio K; Murata A; Shimizu S; Kikuchi T; Yonemitsu K; Shirai D; Nobori C; Tashima T; Goto W; Miura K; Maeda K
Gan To Kagaku Ryoho; 2020 Mar; 47(3):502-504. PubMed ID: 32381929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]